Use of hepatoprotectors during tuberculosis chemotherapy: review of the Russian and international studies
https://doi.org/10.21292/2075-1230-2018-96-10-63-69
Abstract
The article presents the review of the Russian and international studies devoted to the use of hepatoprotectors during anti-tuberculosis treatment, including methionine derivatives and agents containing succinic acid.
About the Authors
A. A. Stаrshinovа
St. Petersburg Research Institute of Phthisiopulmonology; St. Petersburg University
Russian Federation
Russian Federation
Anna A. Starshinova - Doctor of Medical Sciences, Senior Researcher.
2-4, Ligovsky Ave., St. Petersburg, 191036.
Phone: +7 (812) 297-22-63.
E. N. Belyaevа
St. Petersburg Research Institute of Phthisiopulmonology; Tuberculosis Hospital no. 2
Russian Federation
Russian Federation
Ekaterina N. Belyaeva - Junior Researcher.
2-4, Ligovsky Ave., St. Petersburg, 191036.
A. M. Pаnteleev
Tuberculosis Hospital no. 2; Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
Aleksandr M. Panteleev - Doctor of Medical Sciences, Acting Head Doctor.
93, Toreza Ave., St. Petersburg, 194214.
M. V. Pаvlovа
St. Petersburg Research Institute of Phthisiopulmonology
Russian Federation
Russian Federation
Maria V. Pavlova - Doctor of Medical Sciences, Leading Researcher.
2-4, Ligovsky Ave., St. Petersburg, 191036.
References
1. Аbdullaev R.Yu., Vaniev E.V., Kaminskaya G.O., Vasilyeva I.А., Komissarova O.G. Evaluation of functional liver state in adults suffering from new pulmonary tuberculosis when using I and IIB chemotherapy regimens. Probl. Tub., 2009, no. 2, pp. 57-61. (In Russ.)
2. Аbdullaev R.Yu., Chumakova E.S., Komissarova O.G., Odinets V.S. Side effects of anti-tuberculosis drugs damaging liver during treatment of new cases of pulmonary MDR tuberculosis. Ftisiatriya i Pulmonologiya, 2016, no. 1, pp. 34-35. (In Russ.)
3. Balasanyants G.S. Hepatotoxic reactions and hepatoprotective therapy in tuberculosis control. Tuberculosis and Lung Diseases, 2015, no. 8, pp. 48-53. (In Russ.)
4. Ivanova D.A. Nezhelatelnye reaktsii pri lechenii vpervye vyyavlennykh bolnykh tuberkulezom organov dykhaniya: profilaktika, rannyaya diagnostika i kupirovanie. Avtoref. diss. dokt. med. nauk. [Adverse reactions to treatment of new respiratory tuberculosis cases: prevention, early diagnostics and management. Doct. Diss.]. Moscow, 2018, 41 p.
5. Ivanova D.А., Borisov S.E. Profile and risk factors of adverse reactions in new tuberculosis cases receiving treatment. Tuberculosis and Lung Diseases, 2017, no. 6, pp. 46-52. (In Russ.)
6. Ilchenko L.Yu., Okovity S.V. Remaxol: action mechanisms and its use in clinical practice. Part 1. Arkhiv Vnutrenney Meditsiny, 2016, vol. 6, АВМ-2(28), pp. 16-22. (In Russ.)
7. Ilchenko L.Yu., Okovity S.V. Remaxol: action mechanisms and its use in clinical practice. Part 2. Arkhiv Vnutrenney Meditsiny, 2016, vol. 6, АВМ-3(29), pp. 8-18. (In Russ.)
8. Livchane E. Lekarstvennaya neperenosimost, metody eye diagnostiki i korrektsii pri lechenii bolnykh tuberkulezom legkikh protivituberkuleznymi preparatami rezervnogo ryada. Avtoref. diss. kand. med. nauk [Drug intolerance, methods of its diagnostics and management during treatment of pulmonary tuberculosis patients with second line drugs. Cand. Diss.]. Moscow, 2003, 22 p.
9. Ovchinnikova Yu.E., Starshinova А.А., Dovgalyuk I.F. Optimization of chemotherapy regimens for new respiratory tuberculosis in children. Probl. Tub., 2009, vol. 89, no. 1, pp. 36-39. (In Russ.)
10. Pavlova M.V. et al. Efficiency of comprehensive therapy and potential side effects when treating respiratory tuberculosis with multiple drug resistance. Tuberculosis and Lung Diseases, 2015, no. 12, pp. 61-67. (In Russ.)
11. Salogub T.V., Sukhanov D.S., Petrov А.Yu., Kovalenko А.L., Goryacheva L.G., Romantsov M.G. The risk of unfavorable outcomes when performing pharmaco-econmic analysis and safety assessment of remaxol in the therapy of chronic viral liver lesions (based on the materials multi-centered randomized clinical trials). Antibiotiki i Khimioterapiya, 2010, pp. 1-4. (In Russ.)
12. Sukhanov D.S. Anti-oxidant properties of remaxol, reamberin and ademetionine in drug-induced liver lesions in the patients receiving tuberculosis therapy. Eksperimentalnaya i Klinicheskaya Farmakologiya, 2013, vol. 76, no. 4, pp. 45-48. (In Russ.)
13. Sukhanov D.S. Farmakoterapiya lekarstvennykh porazheniy pecheni pri tuberkuleze (eksperimentalno-klinicheskoe issledovanie) Avtoref. diss. dokt. med. nauk. [Pharmacotherapy of drug-induced liver lesions in tuberculosis (experimental clinical trial). Doct. Diss.]. St. Petersburg, 2014, 48 p.
14. Sukhanov D.S., Pavlova M.V., Yablonskiy P.K., Vinogradova T.I. Comparative efficiency of clinical use of reamberin, remaxol and ademetionine in respiratory tuberculosis patients with liver lesions. Antibiotiki i Khimioterapiya, 2013, vol. 58, no. 1-2, pp. 13-18. (In Russ.)
15. Uchaykin V.F., Cherednichenko T.V., Chaplygina G.V., Pisarev А.G. LIV.52 – a new view on its efficiency in acute and chronic viral hepatitis in children. Detskie Infektsii. Аssotsiatsiya Pediatrov-Infektsionistov, 2003, no. 3, pp. 41-44. (In Russ.)
16. Chernokhaeva I.V. et al. Monitoring of side effects during therapy of respiratory tuberculosis with multiple drug resistance when using thioureideiminomethyliiridine perchlorate (perchlozon). Med. Alyans, 2014, no. 2, pp. 59-66. (In Russ.)
17. Common Terminology Criteria for Adverse Events V4.03. Cancer Therapy Evaluation Program. June 14, 2010.
18. Companion handbook to the WHO guidelines for the programmatic management of drug-resistant tuberculosis. World Health Organization, 2014, 448 p.
19. Hosford J.D., von Fricken M.E., Lauzardo M., Chang M., Dai Y., Lyon J.A., Shuster J., Fennelly K.P. Hepatotoxicity from antituberculous therapy in the elderly: A systematic review. Tuberculosis, 2015, vol. 95, pp. 112-122.
20. Javadi M.R., Shalviri G., Gholami K. et al. Adverse reactions of antituberculosis drugs in hospitalized patients: incidence, severity and risk factors. Pharmacoepidemiol. Drug Saf., 2007, vol. 16, suppl. 10, pp. 1104-1110.
21. Ramappa V., Guruprasad P. Hepatotoxicity related to anti-tuberculosis drugs: mechanisms and management. Aithal. J. Clin. Exp. Hepatol., 2013, vol. 3, no. 1, pp. 37-49.
22. Saha A., Margaret Shanthi F.X., Blessed Winston A., Saibal Das, Aniket Kumar, Joy S. Michael, T. Balamugesh prevalence of hepatotoxicity from antituberculosis therapy a five-year. J. Primary Care & Community Health, 2016, pp. 171-174.
23. Santhosh S., Sini T.K., Anandan R. et al. Hepatoprotective activity of chitosan against isoniazid and rifampicin-induced toxicity in experimental rats. Eur. J. Pharmacol., 2007, vol. 572, suppl. 1, pp. 69-73.
24. Svensson R.J., Simonsson U. Application of the multistate tuberculosis pharmacometric model in patients with rifampicin-treated pulmonary tuberculosis. CPT Pharmacometrics Syst. Pharmacol., 2016, vol. 5, no. 5, pp. 264-273.
25. Vilarica A., Pina J., Diogo N. et al. Adverse reactions from antituberculosis drugs. Rev. Port. Pneum., 2007, vol. 13, suppl. 6, pp. 21-22.
26. Wong W.M., Wu P.C., Yuen M.F., Cheng C.C., Yew W.W., Wong P.C., Tam C.M., Leung C.C., Lai C.L. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology, 2000, vol. 31, no. 1, pp. 201-206.
27. Wu S., Xia Y., Lv X., Tang S., Yang Z., Zhang Y. еt al. Preventive use of hepatoprotectors yields limited efficacy on the liver toxicity of anti-tuberculosis agents in a large cohort of Chinese patients. J. Gastroenterol. Hepatol., 2015, vol. 30, no. 3, pp. 540-545.
28. Wu S. et al. Adverse events associated with the treatment of multidrug-resistant tuberculosis: a systematic review and meta-analysis. Am. J. Ther., 2016, vol. 23, no. 2, pp. e521-е530.
Review
For citations:
Stаrshinovа A.A., Belyaevа E.N., Pаnteleev A.M., Pаvlovа M.V. Use of hepatoprotectors during tuberculosis chemotherapy: review of the Russian and international studies. Tuberculosis and Lung Diseases. 2018;96(10):63-69. (In Russ.) https://doi.org/10.21292/2075-1230-2018-96-10-63-69
Views:
1723
Email this article 